公开(公告)号：US10385098B2

公开(公告)日：2019-08-20

申请号：US15771078

申请日：2016-11-30

Applicant: NEURACLE SCIENCE CO., LTD.

Inventor： Jae Young Seong ,  Jong-Ik Hwang ,  Dong-Hoon Kim ,  Gi Hoon Son ,  Yoo-Na Lee ,  Seongsik Yun ,  Arfaxad Reyes-Alcaraz

IPC: C07K7/08 ,  A61K38/00 ,  A61K9/19 ,  A61K9/00 ,  A61P25/06 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30

Abstract: The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.

公开(公告)号：US11248023B2

公开(公告)日：2022-02-15

申请号：US16511976

申请日：2019-07-15

Applicant: NEURACLE SCIENCE CO., LTD.

Inventor： Jae Young Seong ,  Jong-Ik Hwang ,  Dong-Hoon Kim ,  Gi Hoon Son ,  Yoo-Na Lee ,  Seongsik Yun ,  Arfaxad Reyes-Alcaraz

IPC: C07K7/08 ,  A61K38/00 ,  A61P25/28 ,  A61P25/30 ,  A61P25/22 ,  A61P25/18 ,  A61P25/24 ,  A61P25/06 ,  A61K9/00 ,  A61K9/19

Abstract: The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.